Farnier M, et al. - Researchers evaluated the longer-term safety and efficacy of alirocumab by undertaking the ODYSSEY OLE program that included patients diagnosed with heterozygous familial hypercholesterolemia (HeFH) receiving maximally tolerated statins, who had completed one of four phase 3 double-blind parent studies. Alirocumab was given to a total of 985 patients with HeFH (median duration 2.5 years). They identified no unexpected long-term safety concerns with alirocumab compared with previously published data. Findings demonstrate the durability of alirocumab for reducing low-density lipoprotein cholesterol over 3 years (including 1.5 years of parent trials).